Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to Note

Group 1: Stock Performance - Gilead Sciences (GILD) closed at $147.83, reflecting a -1.46% change from the previous day, which is less than the S&P 500's daily loss of 0.94% [1] - The stock has increased by 5% over the past month, outperforming the Medical sector's gain of 2.62% and the S&P 500's loss of 1.3% [1] Group 2: Upcoming Financial Results - Gilead Sciences is expected to report an EPS of $1.86, a 2.76% increase compared to the same quarter last year [2] - The consensus estimate projects revenue of $6.86 billion, reflecting a 2.93% rise from the equivalent quarter last year [2] Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are predicted to be $8.66 per share and revenue is expected to be $30.15 billion, indicating changes of +6.26% and +2.4% respectively from the previous year [3] - Recent adjustments to analyst estimates may indicate shifting dynamics in short-term business patterns, with positive revisions suggesting optimism about the business outlook [3] Group 4: Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 17.33, which is lower than the industry average of 19.56, indicating it is trading at a discount [6] - The current PEG ratio for Gilead is 1.97, compared to the industry average of 1.54, suggesting a higher valuation relative to expected earnings growth [7] Group 5: Industry Ranking - The Medical - Biomedical and Genetics industry holds a Zacks Industry Rank of 137, placing it in the bottom 45% of over 250 industries [7] - The strength of individual industry groups is measured by the Zacks Industry Rank, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [8]